🇺🇸

Distress Insolvency

· daily

US Corporate Distress Financial Stress SEC Filings — July 22, 2026

Both filings in this brief are from US solar and home goods companies facing severe distress, with Nasdaq delisting threats as the common theme. SunPower Inc. received a delisting notice on July 21, 2026, for failing to maintain the $1.00 minimum bid price for 30 consecutive days, triggering a 180-day cure period through January 19, 2027. Purple Innovation, Inc. received a final Nasdaq Hearings Panel decision on July 20, 2026, granting continued listing only if it demonstrates compliance with the $1.00 minimum bid price by July 31, 2026, and executed a 1-for-25 reverse stock split effective July 20, 2026, with its stock opening at $7.12 on a split-adjusted basis. Neither company has provided period-over-period financial comparisons, insider trading activity, forward-looking guidance, or capital allocation data in these filings, limiting quantitative trend analysis. The concentrated risk in the solar and consumer durables sectors suggests broader market headwinds for small-cap companies with weak balance sheets and depressed stock prices. Both filings carry a materiality score of 9/10, indicating imminent risk of equity value destruction if delisting occurs.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 21, 2026

The three filings in this digest all involve Nasdaq compliance issues, signaling a cluster of corporate distress among small-cap issuers. Origin Investment Corp I quickly resolved a technical audit committee deficiency, while Cypherpunk Technologies faces a more serious bid price deficiency with a 180-day cure period and potential reverse split. CN Healthy Food Tech Group Corp. received a delisting determination linked to CSRC review status, representing the highest materiality risk with an appeal deadline of July 23, 2026. No period-over-period comparisons, insider activity, or capital allocation data were available in these filings, limiting trend analysis. The overarching theme is regulatory and listing standard pressures, with CN Healthy Food Tech facing the most existential threat. Investors should monitor the appeal outcome and Cypherpunk's ability to regain compliance within the cure period.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 20, 2026

The July 20, 2026 corporate distress landscape is dominated by acute delisting and bankruptcy events, with three of four filings representing severe liquidity or compliance failures. Smart Powerr Corp. (CREG) faces imminent Nasdaq suspension (July 21) and a move to OTCQB, while Sangamo Therapeutics (SGMOQ) has entered Chapter 11 with a forced asset sale deadline of August 4. SES AI Corp (SES) received a NYSE non-compliance notice but has a six-month cure period, offering a more manageable timeline. In contrast, TEN Holdings (XHLD) has temporarily resolved its Nasdaq equity deficiency via a $6.6M offering, though monitoring continues. The period-over-period data reveals no revenue growth or margin trends across these filings, as all are pre-revenue or distressed. Insider activity is absent, and no capital allocation actions (dividends, buybacks) are reported. The overarching theme is a cascade of small-cap biotech and energy companies failing to meet exchange listing standards, with Sangamo's bankruptcy representing the most terminal outcome. The market implication is heightened risk for micro-cap stocks with low liquidity and reliance on equity raises for compliance.

4 high priority 4 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — July 20, 2026

The single filing in this stream, Sangamo Therapeutics' 8-K, confirms a definitive Chapter 11 bankruptcy and forced asset sale, marking a terminal event for the biotech. The company has no period-over-period comparisons, insider activity, or forward guidance, as the filing focuses solely on court-approved bidding procedures. The key development is the August 4, 2026 bid deadline and potential August 10 auction, creating a binary catalyst for distressed debt and asset buyers. The Nasdaq delisting and OTC trading underscore the collapse in equity value, with no recovery path for common shareholders. This filing represents a pure distressed asset play with no operational turnaround narrative, making it a high-risk, high-reward opportunity for specialized investors.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 17, 2026

The July 17, 2026, digest reveals a severe micro-cap distress cluster, with five companies simultaneously facing Nasdaq delisting or receivership, signaling a potential liquidity and compliance crisis in the small-cap biotech and fintech sectors. Period-over-period data from the filings shows a universal pattern of deteriorating equity bases and market values, with no company reporting positive revenue growth or margin improvement. The most critical development is Fuse Science's complete insolvency and court-ordered receivership, which sets a precedent for aggressive creditor action against shell-like entities. A portfolio-level pattern emerges where four of the five companies (Dare Bioscience, Actuate Therapeutics, Caring Brands, Fold Holdings) are all in the same 180-day compliance window, creating a binary catalyst calendar in January 2027. The absence of any insider buying or positive forward guidance across all filings confirms a complete lack of management confidence, making these high-risk, low-recovery situations for equity holders.

5 high priority 5 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — July 17, 2026

Fuse Science, Inc. has entered a formal insolvency proceeding with the appointment of a receiver by the Clark County District Court, marking a definitive end to its operational viability. The company reported zero assets and zero cash as of December 31, 2026, and has relocated its headquarters and assets abroad, signaling a complete capital erosion. The receiver has been granted sweeping authority to investigate insider transactions, claw back improperly issued shares, and wind down the business, which introduces significant legal and reputational risk for former insiders. This filing represents a total loss for equity holders and underscores the severe consequences of sustained operational failure and potential governance lapses. The lack of any period-over-period improvements, forward guidance, or insider buying reinforces the terminal nature of this situation, making it a clear cautionary case for distressed-debt and event-driven investors.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 16, 2026

The July 16, 2026 digest reveals a severe escalation in corporate distress across small-cap US equities, with three of four filings detailing imminent or actual delisting events. The most critical development is Inotiv, Inc.'s confirmed Chapter 11 plan, which will cancel all existing common equity (35.2M shares) for zero recovery, marking a total loss for shareholders and a stark warning on the risks of distressed biotech/life sciences debt structures. Two additional companies, Cycurion and TG-17 (Our Bond, Inc.), face Nasdaq delisting due to persistent sub-$1.00 bid prices, with Cycurion's situation particularly acute as it has exhausted its compliance extension options after a prior reverse split. The sole positive signal comes from SRx Health Solutions, which resolved its NYSE American deficiency, demonstrating that compliance recovery is possible with operational improvement. A key period-over-period theme is the absence of insider buying across any distressed filer, while the aggregate trend shows a tightening of exchange listing standards, particularly for companies that have already executed reverse stock splits. The market implication is clear: the window for distressed micro-caps to regain compliance is narrowing, and equity holders in these situations face a high probability of total loss.

4 high priority 4 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — July 16, 2026

Inotiv, Inc. has received court confirmation of its prepackaged Chapter 11 plan, marking a definitive end for common equity holders. The plan cancels all 35,172,908 existing shares with zero recovery, while issuing 5,100,000 new shares and warrants to prepetition lenders. The company's Nasdaq delisting was finalized in July 2026, and shares now trade OTC under NOTVQ. This is a total loss event for shareholders, with no forward-looking guidance or insider activity to suggest any recovery. The filing underscores the finality of the restructuring, with no operational or financial metrics to compare, as the company will emerge as a private entity.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 15, 2026

This digest covers four US-listed companies facing acute corporate distress, with three newly published filings since the last brief. The dominant theme is Nasdaq non-compliance and imminent delisting risk, affecting SemiLEDs, SPAR Group, and Triller Group. SPAR Group is the most critical case, having failed to regain compliance with both the bid price and stockholders' equity rules, compounded by shareholder rejection of a reverse stock split, leading to a scheduled delisting on July 23, 2026. Triller Group received a final extension to July 30, 2026, but its history of repeated non-compliance and late filings suggests a high probability of failure. SemiLEDs has a more tenuous reprieve, with Nasdaq monitoring its compliance. Lipella Pharmaceuticals has already filed for Chapter 11 bankruptcy and is selling substantially all assets, with stock trading deemed highly speculative. Across the portfolio, no positive period-over-period trends or insider buying were detected; instead, the data reveals deteriorating equity positions, failed capital allocation votes, and a complete lack of forward-looking guidance, signaling a systemic distress pattern among micro-cap issuers. The market implications are severe: investors in these names face near-total loss of equity value, with SPAR Group and Lipella representing the highest risk of zero recovery.

4 high priority 4 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — July 15, 2026

This brief covers a single filing from Lipella Pharmaceuticals Inc., which filed for Chapter 11 bankruptcy on March 30, 2026, and subsequently entered into an Asset Purchase Agreement with XRAIY to sell substantially all of its assets. The sale was approved by the Bankruptcy Court on June 4, 2026. The company explicitly warns that trading in its common stock during the Chapter 11 case is highly speculative and may bear little or no relation to actual recovery for stockholders. With no period-over-period comparisons, insider trading activity, forward-looking guidance, or capital allocation data available in the enriched filing, the actionable insights are limited to the bankruptcy proceedings and the asset sale. The key development is the court-approved sale, which effectively ends the company's operations and leaves equity holders with likely zero recovery. This is a classic end-stage bankruptcy event with no turnaround potential, making it a high-risk situation for any remaining shareholders.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 14, 2026

Both filings on July 14, 2026, involve voluntary exchange transfers—D-Wave Quantum moving from NYSE to Nasdaq and Trinity Capital moving from Nasdaq to NYSE/NYSE Texas—neither triggered by financial distress or listing non-compliance. No period-over-period financial data, insider transactions, forward guidance, or capital allocation changes were disclosed in either filing, limiting the depth of quantitative trend analysis. The delistings are purely administrative listing venue changes with no operational or financial impact, resulting in neutral sentiment (materiality 4-5/10). For a corporate distress & bankruptcy stream, these events are non-events; no bankruptcy, going concern, or delisting-for-cause signals are present. The digest therefore focuses on the absence of distress signals and the benign nature of these voluntary transfers.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 13, 2026

The three filings paint a stark picture of distress among micro-cap companies listed on Nasdaq, with all three facing delisting or imminent suspension due to non-compliance with listing standards. Pluri Inc., Actelis Networks Inc., and BNB Plus Corp. all received negative delisting or non-compliance notices within a single week (July 7-10, 2026), indicating a concentrated wave of corporate distress. None of the companies provided forward-looking guidance, insider trading activity, or capital allocation data in their filings, suggesting a lack of strategic communication or financial flexibility. The common theme is a failure to meet minimum market value or bid price requirements, with all three companies either already trading on the OTCQB Venture Market or facing imminent transfer. The absence of any positive period-over-period trends or recovery plans underscores the severity of their situations, making these high-risk, low-recovery scenarios for equity holders.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 10, 2026

All four filings in this digest are Nasdaq-listed companies receiving non-compliance or delisting notices, underscoring a concentrated wave of distress among micro-cap and small-cap issuers. GeoVax Labs, NanoVibronix, Lakeside Holding, and Mercer International each face minimum bid price or stockholders' equity violations, with NanoVibronix at the highest risk due to a prior reverse split that disqualifies it from a standard cure period. Lakeside Holding has already received a second 180-day extension, indicating persistent price weakness. No period-over-period financial data, insider activity, capital allocation, or forward-looking guidance was disclosed in these 8-K filings, limiting quantitative trend analysis. The overarching theme is a liquidity and market confidence crisis, with no clear catalysts for recovery and a high probability of at least one delisting event. Investors should monitor these names for potential bankruptcy or going-concern triggers as they exhaust compliance remedies.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 09, 2026

This intelligence stream reveals a severe cluster of corporate distress signals concentrated in micro-cap and pre-revenue biotech companies, with 5 of 8 filings involving Nasdaq/NYSE American non-compliance or delisting threats. The most critical development is the termination of the Shutterstock/Getty Images merger, a high-profile deal collapse driven by UK regulatory conditions, which signals heightened antitrust risk in digital content M&A. The remaining filings paint a bleak picture of liquidity crises: Kyverna Therapeutics is burning cash and extending loan draw deadlines with new revenue covenants, while Nauticus Robotics is issuing 10% cumulative preferred stock to raise capital, indicating desperate financing terms. The three Nasdaq deficiency notices (Onfolio, Hydrofarm, Prairie Operating) and one NYSE American compliance plan (Splash Beverage) represent a systemic wave of micro-cap distress, with all four companies trading below $1.00 and facing potential delisting. Period-over-period data from the enriched filings shows no positive revenue or margin trends—only deteriorating liquidity, increasing debt burdens, and regulatory overhang. The overarching theme is a 'distress cascade' in small-cap equities, where falling stock prices trigger listing compliance issues, which in turn restrict capital access and accelerate financial deterioration.

8 high priority 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 08, 2026

The 31 filings reveal a bifurcated corporate landscape: while several companies (AEP Texas, Sterling Infrastructure, Energy Transfer) secure large-scale financing for growth and infrastructure, a significant cluster faces acute distress signals—Nasdaq non-compliance (Borealis Foods, Nocera, Future FinTech), high-cost emergency financing (XCF Global, Newton Golf, Clean Energy Technologies), and failed clinical/SPAC deals (Alector, Aimei Health). Period-over-period data is sparse, but insider activity shows CEO Woodman personally lending $20M to GoPro, a strong vote of confidence. Capital allocation trends include debt refinancings (Civeo, Voyager, CPKC) and bolt-on M&A (Byrna, Tarsus, ReposiTrak). The distressed cohort is concentrated in micro-cap and pre-revenue biotech/tech, while mid-cap energy and infrastructure firms demonstrate financial strength.

31 high priority 31 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 07, 2026

The July 7, 2026, filing batch reveals a bifurcated corporate landscape. On one side, several companies are executing strategic balance sheet improvements, including debt refinancings (Oceaneering, Oncology Institute, UGI Corp), credit facility expansions (Suncrete, Postal Realty Trust), and a major non-dilutive royalty deal (MeiraGTx). Conversely, a cluster of filings signals acute financial distress, characterized by high-cost emergency financing (NextNRG, CDT Equity, Polar Power), equity-based debt settlements (Interactive Strength), and going-concern-like PIPE offerings (Vivos Therapeutics). A notable sector-wide trend is the coordinated benchmark provider switch by seven 21Shares crypto ETFs, a purely operational shift with no financial impact. The most material M&A activity includes Vertex's $10B acquisition of Crinetics and Iridium's acquisition of Aireon, both strategically significant. Overall, the data points to a 'haves and have-nots' dynamic where well-capitalized firms are securing favorable terms, while cash-strapped companies are resorting to dilutive or high-cost capital, a classic late-cycle distress signal.

44 high priority 44 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 06, 2026

This digest covers 50 SEC filings from July 6, 2026, revealing a pronounced wave of corporate distress across small-cap and micro-cap companies, particularly in the biotech and technology sectors. Key themes include a cluster of Nasdaq non-compliance notices (CISO Global, Cytosorbents, Polar Power), aggressive debt restructuring under duress (BioXcel Therapeutics, P3 Health Partners), and dilutive financing rounds (FreeCast, Mitesco, iPower). Period-over-period comparisons, where available, show severe liquidity constraints, with companies like Polar Power reporting only $144,000 in stockholders' equity against a $2.5M minimum. Insider activity is mixed, with some executives providing cash infusions (Greenpro Capital) while others are issuing shares to cancel debt (IGC Pharma). The M&A landscape is bifurcated, with a large, healthy acquisition of Crinetics by Vertex ($10B) contrasting with distressed asset sales and reverse mergers (ClearOne/Cortigent, Professional Diversity Network). Overall, the data signals a high-risk environment for marginal companies, with a clear catalyst calendar of compliance deadlines and restructuring milestones through late 2026.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 02, 2026

The 50 filings reveal a pronounced bifurcation in corporate health: while several companies are securing substantial capital (BridgeBio $1B, NextDecade $3.5B, Neurogene $134.8M) and extending credit lines (Haverty +$20M, Cheniere +$500M), a cluster of distressed firms are fighting for survival through high-cost debt (American Rebel 36.6% effective rate), repeated maturity extensions (CareView 15th amendment), and reverse stock splits (Snail 1-for-5). Distress signals dominate: 5 companies received Nasdaq deficiency notices (RenovoRx, HeartBeam, ALT5 Sigma, Boxlight, Snail), 1 approved liquidation (Origin Materials), and 1 faces delisting (Boxlight). Period-over-period data is sparse but shows HUMBL's revenue growing 20% YoY while losses widen, and Centrus Energy securing a $900M DOE contract but with first capacity not until 2029. Insider activity is limited but includes CEO Nicholas Liuzza receiving shares at a premium in Beeline Holdings. The overarching theme is capital access as a differentiator—well-capitalized firms are investing for growth, while cash-strapped firms resort to dilutive or expensive financing.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 01, 2026

This digest of 50 pre-analyzed SEC filings from July 1, 2026, reveals a pronounced bifurcation in corporate health. On one side, a wave of distress signals is concentrated among small-cap and micro-cap companies, with 8 filings directly involving bankruptcy, going concern, delisting, or severe liquidity crises. These include InnSuites Hospitality Trust (IHT) receiving a delisting notice due to a stockholders' deficit, Stratus Properties (STRS) voluntarily liquidating, and multiple companies like Nuvve (NVVE) and Trio Petroleum executing reverse splits or taking on high-interest debt. Conversely, a separate cohort of larger, more established firms is proactively strengthening their balance sheets and extending maturities, exemplified by Peabody Energy (BTU) upsizing and extending its credit facility, FTI Consulting (FCN) increasing its revolver to $1.5B, and Kohl's (KSS) extending its facility by five years. A third theme is the aggressive use of dilutive financing, particularly through convertible notes and equity lines, by companies like HIVE Digital, Energy Vault, and OneMedNet, signaling a 'growth at all costs' or 'survival financing' strategy. The overall picture is one of a market where access to cheap capital is highly uneven, creating both acute risks and selective opportunities in distressed assets and well-capitalized survivors.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 30, 2026

This digest of 50 SEC filings reveals a pronounced theme of corporate distress and strategic restructuring across US public companies. A significant cluster of firms are actively managing liquidity and leverage through debt refinancing, asset sales, and equity offerings, often under duress. Key period-over-period trends include tightening financial covenants (e.g., HighPeak Energy's leverage ratio step-down) and a shift towards dilutive financing (e.g., Quantum Computing's authorized share increase, Eos Energy's rights offering). The most critical developments are multiple Nasdaq delisting warnings (Gulf Resources, SolarMax Technology) and a high volume of distressed asset sales (Sadot Group, Advanced Biomed) for nominal cash, signaling severe financial strain. A portfolio-level pattern is the reliance on single-lender credit facilities and complex, contingent financing structures, which introduce significant execution risk.

50 high priority 50 total filings